2021 IPO
Impel NeuroPharma Stock
Medical device company developing a direct nose-to-brain delivery
Sign up today and learn more about Impel NeuroPharma Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Impel NeuroPharma Stock
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery.
Funding History
| January 2010 | $305K |
|---|---|
| October 2011 | $500K |
| August 2012 | $25K |
| November 2013 | $2.6M |
| October 2015 | $0 |
| August 2016 | $1.1M |
| December 2016 | $36.0M |
| December 2018 | $67.5M |
Management
Chief Business Officer
Richard Haiduck
Director of R&D
Alan Brunelle
Co-Founder & CEO
Michael Hite
Co-Founder & Chief Scientific Officer
John Hoekman
President & CEO
Jon Congleton
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
